Neuronetics

Neuronetics EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Neuronetics (STIM) as of Oct 27, 2026 is 16.03 %. In the previous year, Year-over-Year EBITDA Growth was -19.27 % — a change of -183.22% (higher).

EBITDA Growth YoY

16.03 %

YoY

-183.22%

Last updated:

Year-over-Year EBITDA Growth of Neuronetics is 2025 16.03 % . Year-over-Year EBITDA Growth of Neuronetics was 2024 -19.27 % . It decreases by -183.22% higher compared to the previous year.

The Neuronetics EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
-54.02 USD
Jan 1, 2019
-38.46 USD
Jan 1, 2020
18.85 USD
Jan 1, 2021
-21.56 USD
Jan 1, 2022
-20.57 USD
Jan 1, 2023
9.09 USD
Jan 1, 2024
-19.27 USD
Jan 1, 2025
16.03 USD
The Neuronetics EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
16.03 %-183.22%
-19.27 %-312.03%
9.09 %-144.17%
-20.57 %-4.57%
-21.56 %-214.33%
18.85 %-149.02%
-38.46 %-28.80%
-54.02 %+28.86%
-41.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuronetics Stock analysis

What does Neuronetics do? Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuronetics stock

Year-over-Year EBITDA Growth of Neuronetics is 16.03 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Neuronetics since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Neuronetics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Neuronetics

All Key Metrics — Neuronetics